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Electronic medical recordAbstract Objective: To determine the PPVs of selected ten medication antidote signals in recog-
nizing potential ADRs and comparison of their sensitivity with manual chart analysis, and volun-
tary reporting recognizing the same ADRs.
Method: The inpatient EMR database of internal medicine department was utilized for a period
of one year, adult patients prescribed at least one of the ten signals, were included in the study, reci-
pient patients of antidote signals were assessed for the occurrence of an ADR by Naranjo’s tool of
ADR evaluation. PPVs of each antidote signal were veriﬁed.
Result: PPV of Methylprednisolone and Phytonadione was 0.28, Metoclopramide and Potas-
sium Chloride – 0.29, Dextrose 50%, Promethazine, Sodium Polystyrene and Loperamide – 0.30,
Protamine and Acetylcysteine – 0.33. In comparison of conﬁrmed ADRs of antidote signals with
other methods, Dextrose 50%, Metoclopramide, Sodium Polystyrene, Potassium Chloride, Meth-
ylprednisolone and Promethazine seem to be extremely signiﬁcant (P value > 0.0001), while ADRs
of Phytonadione, Protamine, Acetylcysteine and Loperamide were insigniﬁcant.
Conclusion: Antidote medication signals have deﬁnitive discerning evaluation value of ADRs
over routine methods of ADR detection with a high detection rate with a minimum cost; Their inte-
gration with hospital EMR database and routine patient safety surveillance enhances transparency,
time-saving and facilitates ADR detection.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).What is already known about this subject:
 Hospitalized patients are vulnerable to experience ADRs,
which frequently conclude in severe ADRs.
 Identiﬁcation of ADRs contributes to the reduction in mor-
bidity, mortality and economic impact.
Table 1 List of drugs selected for the study as medication
antidotes administered by parenteral route except Loperamide.
Medication antidotes Signals
Dextrose 50% Hypoglycemia
Metoclopramide Nausea and vomiting in relation to drug use
Methylprednisolone Hypersensitivity skin reaction
Phytonadione Bleeding with warfarin
Protamine Heparin induced toxicity
Sodium Polystyrene Drug induced hyperkalemia
Potassium Chloride Drug induced hypokalemia
Promethazine Hypersensitivity skin reaction
Acetylcysteine Paracetamol toxicity
Loperamide Antimicrobial induced diarrhea
516 L.M. Khan et al. Constraints in the methods of detecting adverse drug reac-
tions, necessitate exploration for an automated method to
revamp drug safety.
What this study adds:
 Antidote signals have discerning evaluation value of ADRs
over routine methods, with high detection rate and mini-
mum cost.
 Every fourth evaluation of antidote signal culminates in a
conﬁrmed ADR.
 Their integration with hospital EMR database and routine
patient safety surveillance enhances transparency, time-
saving and facilitates ADR detection.
1. Introduction
Of all the counteractive harm to hospitalized patients, contri-
bution of drugs as a source of adverse drug reactions (ADRs)
is highly alarming (Eliasson, 2006; Lopez et al., 2006). They
are the subdued cost of drug therapy, in addition, they are cou-
pled with, unconstrained depressing effects on morbidity and
mortality of hospitalized patients (Khan, 2013; Wester et al.,
2008; Davies et al., 2009) and the top of it, an increase in
resource utilization (Bond and Raehl, 2006; Kra¨henbu¨hl-
Melcher et al., 2007; Rodriguez-Monguio et al., 2003). Hospi-
talized patients are more vulnerable to experience ADRs and
quite often concluding in the form of severe ADRs (Khan,
2013; Bavdekar and Karande, 2006). Ubiquitously, judicious
identiﬁcation of ADRs signiﬁcantly contributes to the reduc-
tion of its severity, morbidity and mortality as well as its eco-
nomic impact (Khan, 2013; Bavdekar and Karande, 2006;
Avery et al., 2011). Knowledge of pharmacovigilance is
responsible to recognize, appraise, realize and avoid ADRs
with the eventual mean to develop secure and rational utiliza-
tion of medication (Khan, 2013; Avery et al., 2011; Mehta
et al., 2008). Contemporary methods of pharmacovigilance
have certain limitations reminiscent of under reporting, inabil-
ity to ﬁnd the incidence rate, size of the population exposed
and biased in collection of drug exposure (Montastruc et al.,
2006; Smyth et al., 2012). Pharmacovigilance gives a critical
gauge of the burden of drug induced morbidity and about half
of ADRs could be avoided with improved prescription care
(Khan, 2013; Smyth et al., 2012; Chien and Ho, 2011). Detec-
tion of ADRs is a critical task and furthermore worldwide
observation methods are heavily dependent on voluntary
reporting that is reminiscent of signiﬁcant underreporting of
the factual prevalence of ADRs (Montastruc et al., 2006;
Aagaard and Hansen, 2010). In post marketing surveillance,
there is a progressive escalation of quantitative methods, such
as signal detection of ADRs, principally due to availability of
large clinical databases of electronic medical records (EMRs)
(Hauben and Bate, 2009). It is characterized by potential
strength of abundant sample size, virtually inexpensive and
devoid of recall or individual bias, and moreover inpatient
EMR data could speciﬁcally afford precise diagnosis, exact
laboratory and radiological reports, literal dosage, administra-
tion time and other noticeable actions throughout hospitaliza-
tion of patients (Strom and Kimmel, 2006).In view of the aforementioned recompenses, medication
antidote signals are utilized by the healthcare providers as
a supplementary mechanism to detect ADRs (Handler
et al., 2007). This is also recommended for recognition of
ADRs by the Institute for Healthcare, a pioneer in patient
safety (Rozich et al., 2003; Takata et al., 2008). Furthermore,
clinicians can focus mainly on those antidote medication sig-
nals which are more efﬁcacious and precise to identify ADRs
rather than evaluating trivial antidote medication signals
(Bates et al., 2003). The objectives of this study were to ﬁnd
out the PPVs of selected ten medication antidote signals with
the intention of exploring their signiﬁcance in recognizing
potential ADRs. In addition to this, to explore the compar-
ison of the sensitivities of other ADR detection methods
which include manual chart analysis, and voluntary report-
ing, and recognizing the same ADRs by utilization of the
hospital EMR database.
2. Method
The inpatient EMR database of internal medicine department
of King Abdulaziz University Hospital was utilized from Jan
01, 2013 to Dec 31, 2013. The database consists of 7587 adults,
hospitalized patients with 37543 prescriptions. The informa-
tion system of the database permits to get the information of
the admission and discharge notes of the patient, patient’s his-
tory, drug prescription and clinicians’ observations.
2.1. Veriﬁcation of antidote signals evaluated
A professional group of experts comprising three clinical phar-
macologists and one medical internist critically studied and
randomly approved ten drugs among the 362 drugs utilized
in the hospitals with high frequencies, as antidote medication
signals for evaluation, however, selection of antidote signals
was based on previous analogous studies (Rozich et al.,
2003; Institute for Safe Medication Practices, 2013;
Morimoto et al., 2004). All adult patients of either sex were
included in the study, who were prescribed at least one of
the ten signals (Table 1).
2.2. Potential adverse drug reaction detection procedure
Recipient patients of antidote signals were assessed for the
occurrence of an ADR by Naranjo’s tool of ADR evaluation
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ship is subsequently judged as ‘‘deﬁnite, probable, possible
or unlikely prior to be considered as ADR (Naranjo
et al., 1981). PPVs of each antidote signal were veriﬁed.
Study procedure designed was agreed by the institutional
ethics committee. Discretion of information obtained was
secured during the study. Suitable study design, thus devel-
oped for the detection of antidote medication signal was
validated by accomplishing a pilot study of 50 patients
from EMR database.
Furthermore, for a comparative analysis of the
sensitivity of ADRs detected by antidote signals with
common methods of ADR detection, retrospective analysis
of the association of a signal with the occurrence of an
ADR (Dextrose 50% with hypoglycemia) was carried out
from obvious records depicted in the progress remarks of
patients’ chart and the database of hospital’s administration
to review ADRs reported by voluntary reporting system.
The evaluation of severity of ADRs was done by the
utilization of Hartwig’s scale (Hartwig et al., 1992), while
assessment of preventable ADRs was performed by the
method of Schumock and Thornton (1992).
2.3. Statistical analysis
Patient demographic information was scrutinized by the uti-
lization of SPSS data version 19.0 and the results were
expressed in absolute number and percentages. Regarding
PPVs, they were computed as quotients, where the episodes
of an antidote signal recognized as an ADR were taken as
the numerator and the number of signals as the denomina-
tor. The entire data were analyzed and comparison of sen-
sitivities of the common methods of ADRs with ADRs
detected by antidote signals was executed by the utilization
of Fisher’s exact test for signiﬁcant association between
groups (P< 0.05).Figure 1 Demographic data of 7589 patients3. Results
3.1. Characteristics of study population
(Fig. 1) The total population of patients acquired in this study
from the database during a period of one year was 7587, com-
prising 4022 males and 3565 females, ethnically 6297 were Sau-
dis and 1290 were non-Saudis. The average age of this
population was 62 ± 18 years, and the average duration of hos-
pital stay of these patients was determined as 21 (6–35) days.
3.2. Number of antidote medication signals detected
During the period of one year of study 362 drugs were admin-
istered to the patients, the total number of antidote medication
signals detected was 1019, of them 302 were recognized as
ADRs with an average PPV of 0.29.
3.3. Sensitivity, speciﬁcity and positive predictive value of each
medication antidote signal
(Table 2) The highest sensitivity of antidote signals was
observed with Acetylcysteine 100 (30.5–100), Protamine 100
(30.5–100), Potassium Chloride 100 (95.9–100) and the lowest
sensitivity was observed with Phytonadione 71.4 (53.7–85.3)
and Loperamide 60 (15.4–93.5). This study divulges the overall
speciﬁcity of antidote medication signals as 58.8 (56.5–61.2),
the highest speciﬁcity of antidote medication signals was
observed with Protamine and Acetylcysteine as 99 (98.3–
99.6) and Loperamide 99 (98.2–99.5), while lowest speciﬁcity
was observed for Sodium Polystyrene 86.1 (83.9–87.9) and
Potassium Chloride 77.4 (75.1–79.6). However, speciﬁcity of
other signals descends in the transitional category, like
Dextrose 50%, 94.1 (92.6–95.5), Methylprednisolone 91.4
(89.6–92.9) and Phytonadione 92.1 (90–93.6). Concerning therecipient of speciﬁc antidote medications.
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as in the range of 0.16–0.54, Phytonadione and Methylprednis-
olone had shown the lowest PPV of 0.28 (0.11–0.43)
while Protamine revealed the highest PPV of 0.33
(0.18–0.62).
3.4. Objective analysis and comparison of ADRs sensitivities,
perceived by diverse methods
(Table 3) From the total 1019 antidote signals 302 were iden-
tiﬁed as ADRs by Naranjo’s tools of ADR evaluation, 41
ADRs were recognized from patients’ progress remarks, while
23 ADRs were authenticated as voluntarily reported. In
comparison of conﬁrmed ADRs of antidote signals with other
methods (within the group analysis), ADRs of Dextrose 50%,
Metoclopramide, Sodium Polystyrene, Potassium Chloride,
Methylprednisolone and Promethazine seem to be extremely
signiﬁcant (P value > 0.0001), while ADRs of Phytonadione,
Protamine, Acetylcysteine and Loperamide were found to be
insigniﬁcant.Figure 2 Bar diagram depicting the preventable ADRs and severit
ADRs.
Table 2 Depicting sensitivity, speciﬁcity and positive predictive val
Antidote signals Antidote signals conﬁrmed as ADRs Se
Acetylcysteine 03 10
Dextrose 50% 19 82
Methylprednisolone 27 90
Metoclopramide 62 93
Phytonadione 25 71
Potassium Chloride 89 10
Promethazine 21 95
Protamine 03 10
Sodium Polystyrene 50 94
Loperamide 03 60
Average (SD) 30.2 (28.5) 933.5. Preventable ADRs and Severity of ADRs from antidote
medication signals conﬁrmed as ADRs
This study revealed the severity of ADRs in the range of
4.7–26.3%; most of them were related to the administration of
Dextrose 50% and minimum with Promethazine (Fig. 2).
Regarding preventable ADRs, Protamine, Acetylcysteine and
Loperamide seem to be associated with maximum preventable
ADRs–66.6%, while minimumpreventable ADRswere depicted
with the utilization of Sodium Polystyrene as 26% (Fig. 2).
4. Discussion
Pharmacovigilance is an indispensable constituent of patient
care and surveillance and therefore excellent assertive pharma-
covigilance methods are required to enhance the crucial aspect
of drug safety with the prime aim of avoiding potential ADRs
(Khan, 2013; Pal et al., 2013). The current lifecycle approach
for various therapeutic agents necessitates a customary safety
monitoring and contemporarily this is best managed by ay of ADRs detected by antidote medication signals conﬁrmed as
ues of ten medication antidote signals.
nsitivity (95% CI) Speciﬁcity (95% CI) PPV (95% CI)
0 (30.5–100) 99.1 (98.3–99.6) 0.33 (0.18–0.62)
.6 (61.2–94.9) 94.1 (92.6–95.5) 0.30 (0.16–0.54)
(73.4–97.8) 91.4 (89.6–92.9) 0.28 (0.11–0.43)
.9 (85.2–98.3) 98.2 (97.2–98.9) 0.29 (0.13–0.47)
.4 (53.7–85.3) 92.1 (90 93.6) 0.28 ((0.11–0.43)
0 (95.9–100) 77.4 (75.1–79.6) 0.29 (0.13–0.47)
.5 (77.1–99.2) 93.6 (91.9–94.9) 0.30 (0.16–0.54)
0 (30.5–100) 99 (98.3–99.6) 0.33 (0.18–0.62)
.3 (84.3–98.7) 86.1 (83.9–87.9) 0.30 (0.16–0.54)
(15.4–93.5) 99 (98.2–99.5) 0.30 (0.16–0.54)
(89.7–95.5) 58.8 (56.5–61.2) 0.29 (0.16–0.54)
Table 3 Comparison of the sensitivities of common methods of ADR detection with ADRs detected by antidote signals.
Antidote signals Antidote signals
conﬁrmed
as ADRsª
Voluntarily reported
ADRs (%)
Obvious ADRs recognized
from progress notes of the
patients (%)
*P-value
Dextrose 50% 19 0 (0) 04 (21) 0.0001***
Metoclopramide HCl 62 04 (6) 07 (11) 0.0001***
Methylprednisolone 27 03 (11) 06 (22) 0.0017**
Phytonadione 25 10 (40) 04 (16) 1.0000§
Protamine 03 0 (0) 01 (33) 0.2500§
Sodium Polystyrene 50 03 (6) 15 (30) 0.0001***
Potassium Chloride 89 0 (0) 07 (8) 0.0001***
Promethazine 21 01 (5) 07 (33) 0.0001***
Acetylcysteine 03 0 (0) 01 (33) 0.2500§
Loperamide 03 02 (67) 0 (0) 0.1165§
Total ADRs 302 23 (8) 52 (17) 0.0001***
ª ADRs conﬁrmed using the agreement of Naranjo’s scale causality assessment tool.
* P-value was determined by Fischer exact test, within the group analysis of ADRs detected by medication antidote signals, review charts and
voluntarily reported.
** Very signiﬁcant.
*** Extremely signiﬁcant.
§ Not statistically signiﬁcant.
ADR detection by medication antidote signals 519spontaneous reporting system (Alj et al., 2007; Ha¨rmark and
van Grootheest, 2008). Nevertheless, this highly accepted
method has inherent limitations (Hazell and Shakir, 2006;
Khan et al., 2012). It is highly imperative to incorporate sup-
plementary methods to scrutinize medicine safety (Lopez
et al., 2006; Rodriguez-Monguio et al., 2003). Trigger tools
method had revealed to be quite superior to voluntary report-
ing system with a 50 fold higher ability to detect ADRs both in
hospitalized adults and pediatric patients (Rozich et al., 2003;
Khan et al., 2012; Resar et al., 2006; Sharek et al., 2006). This
approach had received recommendation of both Institute for
heaithcare improvement (IHI) and Institute of Medicine for the
detection of hospital acquired ADRs (Institute of Medicine
Report, 2004; Institute for Healthcare improvement, 2009).
Signals produced by the ADRs trigger tools and obtained
from electronic medical record database are deemed to provide
the opportunity not only for the detection of unknown, rare
and severe ADRs; but also have additional beneﬁts of high
detection rate with minimum cost (Hauben and Bate, 2009;
Rozich et al., 2003; Khan et al., 2012).
The propensity with which this study remarkably revealed
substantial comparison of PPVs for almost all the medication
antidotes in concordance to the results of past studies (Handler
et al., 2007; Rozich et al., 2003), signiﬁcantly demonstrated its
prime utility in the prompt detection of ADRs. Furthermore,
importance of effectiveness of signals, their speciﬁcity and sen-
sitivity in the detection of ADRs from EMR database was
highlighted in a recent study (Park et al., 2011), similar reﬂec-
tions were observed in our study with high sensitivity of seven
medication antidotes and high speciﬁcity of eight medication
antidotes acquired from EMR database.
It needs to be emphasized that, utilization of medical anti-
dotes to identify potential ADRs in hospitalized patients, dis-
tinctly vary between the multiple discipline of hospitals like
general wards, medical, pediatric and surgical ICUs as well
as nursing home settings (Handler et al., 2007). In comparison
to the other medication antidotes, the frequency of ADR
detection of Protamine, Acetylcysteine and Loperamide, in
our study was found to be low (Table 2), due to infrequentuse in general wards of internal medicine, notwithstanding
their PPVs are quite comparable to the results of other studies
(Handler et al., 2007; Jha et al., 2001).
The average PPVs of the ten medication antidotes selected
in our study was found to be 0.29 (0.16–0.54), this is in quite
close approximation with other similar studies (Handler
et al., 2007; Takata et al., 2008). The PPVs of Dextrose 50%
in our study was revealed as 0.30 (0.16–0.54), this seems to
be quite consistent with the ﬁndings of a systematic review
of 12 studies with ten medications and seven antidotes and
other studies (Handler et al., 2007; Lewis et al., 2004; Rea
et al., 2007), depicting PPVs of 0.33 (0.27–0.27). The PPVs
for Phytonadione perceived in our study was 0.28 (0.11–
0.43), which is at parity with other studies including the 3 stud-
ies of a systematic review, in the range of 0.02–0.30 (Handler
et al., 2007; Hartis et al., 2005). Promethazine in our study
excludes its utilization in the patients as sedative–hypnotic
and by oral route, which makes its indication more speciﬁc
for allergic reactions, its PPVs were determined as 0.30
(0.16–0.54), and in several studies, remarkable comparative
PPVs of antihistaminics were observed in a similar range
(Handler et al., 2007; Jha et al., 2001).
Hyperkalemia and hypokalemia observed in hospitalized
patients exclusively after medications are quite evident by the
utilization of Sodium Polystyrene and Potassium Chloride to
avert the development of cardiac arrhythmias. The PPV of
Sodium Polystyrene depicted in our study was 0.30 (0.16–
0.54) and the PPV of Potassium Chloride was 0.29 (0.13–
0.47); furthermore, it was fairly noticeable that their number
of signals conﬁrmed as ADRs was also quite high, while com-
parative PPV of Sodium Polystyrene in another study was
revealed in the range of 0.06–0.12 (P-value < 0.5) and PPVs
of Potassium Chloride in 2 studies were shown as 0.03–0.03
(P-value < 0.5), nevertheless both the values were slightly
lower than our ﬁndings (Handler et al., 2007).
Moreover, it was notable that due to most common use in
our hospital, we selected Methylprednisolone as a medication
antidote in contrast to oral and topical steroids utilized in two
studies of systematic review (Handler et al., 2007), and the
520 L.M. Khan et al.PPV of our study in the range of 0.11–0.43 was a comparative
reﬂection of their observation. It needs to be emphasized that,
signals of Metoclopramide, Acetylcysteine and Loperamide
were considered only after authentication of their utilization
for drug induced ADRs. Metoclopramide was commonly uti-
lized as anti-emetic, demonstrated its PPV as 0.29 (0.13–0.47)
in our study, which was evidently lower than the PPVs of anti-
emetic drugs 1.55 (0.80–2.69) observed in a study (Takata
et al., 2008). However, this disparity was statistically insigniﬁ-
cant (P-value < 0.5). Finally, the only antidote administered
by the oral route in this studywas Loperamide, and the observed
PPV was 0.26 (0.11–0.34), which seems to be discreetly higher
than that observed in the three recent studies (Handler et al.,
2007), depicting PPV in the range of 0.09 (0.06–0.13), although
the difference was statistically not signiﬁcant (P-value < 0.5).
Evidently, consistent with the ﬁndings of systematic review
(Handler et al., 2007), this study reveals that, considering the
PPV of Methylprednisolone and Phytonadione, Metoclopra-
mide, Potassium Chloride, Dextrose 50%, Promethazine,
Sodium Polystyrene and Loperamide seem to be quite realistic
in recognition of potential ADRs in hospitalized patients in
general wards. Additionally, it is also notable from this study
that relatively every fourth evaluation of antidote signal culmi-
nates in a conﬁrmed ADR.
Secondly, our results of comparative analysis of ADRs by
different methods (Table 3), with quite fairness have depicted
the superiority of seven out of ten antidote signals over other
methods like chart review and voluntary reporting methods.
Distinctly this reiterates and reinforces the perception that med-
ication antidote signals characterize the most robust method to
assess the EMR database for detection of ADRs. Furthermore,
potential beneﬁts are inconsequential if this method fails to
improve the quality of healthcare with reduction of healthcare
costs. Such method amazingly reduced healthcare cost by
$760,000 per year in a teaching hospital (Kaushal et al., 2006).
Their ability to identify ADRs is substantially greater than the
well known established methods and this could, not only form
the basis for tracking ADRs from EMR database, but also pro-
vides the groundwork for evidence based prevention method to
reduce the risk of ADRs to our inpatients (Takata et al., 2008;
Park et al., 2011; Szekendi et al., 2006).
Finally, determination of preventable ADRs in all epidemi-
ological studies appears to be crucial with the aim of reinforc-
ing the rationality of drug therapy and eventually augmenting
drug safety (Khan, 2013; Chien and Ho, 2011). Furthermore,
this vital aspect is additionally strengthened by including
assessment of severity of ADRs in any study, to facilitate rec-
ognition of critical areas by healthcare professionals for appro-
priate intervention to vitalize pharmacovigilance (Khan, 2013;
Khan et al., 2012). Aforementioned statements were appar-
ently fulﬁlled in our study with the detection of preventable
ADRs by antidote signals in the range of 26–66.6% (Fig. 2).
Other similar studies have also revealed the median prevent-
ability of ADRs in hospitalized patients in the range of 35–
46% (Kra¨henbu¨hl-Melcher et al., 2007; Mehta et al., 2008),
and the range of severity of ADRs perceived by antidote sig-
nals in our study was 4.7–26.3%, (Fig. 2) almost identical with
nine studies of hospitalized adult patients in a recent system-
atic review (Khan, 2013). In consequence of the above ﬁndings
it seems to be quite comprehensible that assessment of these
vital components of ADRs is indispensable for drug safety.
Therefore, effective emphasis and alertness of these factorswould play an important role in reducing the burden of ADRs,
reduction of health care cost with enhanced quality care of the
patients (Khan, 2013; Rodriguez-Monguio et al., 2003).
The number of signals detected byAcetylcysteine, Protamine
andLoperamide, was observed to be very less in this study, how-
ever the reason could be their infrequent use in general wards in
comparison to ICU setting, whereas selection criteria were
based on high frequency utilization in hospitals, nevertheless
antidote signals were randomly selected. Furthermore, utiliza-
tion of antidote signals incorporates data study of every patient,
this is not feasible for conducting large epidemiological studies,
nevertheless hospital EMR database could make it practicable.
Conversely, our study seems to be signiﬁcant in affording
inclusive acquaintance on the importance of medication anti-
dote signals in detecting hospital acquired ADRs in adults.
Furthermore, comparison of ADRs detected by antidote med-
ication signals with multiple data sources may facilitate ADR
detection rates, in view of the fact that still; deﬁnitive standards
for identiﬁcation of ADRs are yet to be established. The com-
prehensive information of individual antidote signal could be
utilized by healthcare team in hospitals, to be incorporated in
their system in order to magnify ADR detection strategies, fur-
ther studies are required to improvise and augment the perfor-
mance characteristics of individual medication antidote signal.
5. Conclusion
 Antidote medication signals have deﬁnitive discerning eval-
uation value of ADRs over routine methods of ADR
detection.
 Relatively every fourth evaluation of antidote signal culmi-
nates in a conﬁrmed ADR.
 They are also characterized by a high detection rate with
minimum cost; their integration with hospital EMR data-
base can further enhance their transparency and time
effectiveness.
 Hence, they are recommended to be incorporated in the
routine patient safety surveillance system to facilitate
ADR detection.Disclosure
There is no conﬂict of interest in this study.
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